Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Docetaxel in EGFR Wild-type Advanced NSCLC
NCT03624309Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03624309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624309.